Everything below concerns peptide backbone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
== Education == In 1978, Schleip became Germany's first certified rolfer at the Rolf Institute and in 1983 became a Certified Advanced Rolfer in the field of Structural Integration. Schleip graduated with a degree in psychology from Heidelberg University in 1980. From 1984 to 1987 he trained as a Feldenkrais teacher and became a Certified Feldenkrais Practitioner in the field of Sensorimotor Facilitation from the International Feldenkrais Guild in 1987. In 2006, he earned his doctorate in human biology from the University of Ulm. That year he received the "Vladimir Janda Prize for Musculoskeletal Medicine" for research he performed with Werner Klingler. In 2023, he was appointed to a research professorship in the department for Health & Psychology for the university by the Diploma University of Applied Sciences.
Guzmán later examined Peck's herbarium specimen, and in his comprehensive 1983 monograph on Psilocybe, concluded that Peck had misidentified it with the species now known as Panaeolina foenisecii. P. semilanceata is much less common in South America, where it has been recorded in Chile. It is also known in Australia (where it may be an introduced species) and New Zealand, where it grows in high-altitude grasslands. In 2000, it was reported from Golaghat, in the Indian state of Assam. In 2017, it was reported from Charsadda, in the Pakistani province of Khyber Pakhtunkhwa.
Xi has formulated the new concept for development, stressing the importance of high-quality development rather than "inflated growth". He has stated China has abandoned a growth-at-all-costs strategy which Xi refers to as "GDP heroism". Instead, Xi said other social issues such as environmental protection are important. Xi has made eradicating extreme poverty through targeted poverty alleviation a key goal. In 2015, he launched the battle against poverty. The campaign concluded by 2021, when Xi declared a "complete victory" over extreme poverty, saying nearly 100 million have been lifted out of poverty under his tenure, though some experts said China's poverty threshold was lower than that of the World Bank. In 2020, premier Li Keqiang, citing the National Bureau of Statistics (NBS) said that China still had 600 million people living with less than 1000 yuan ($140) a month, although The Economist said the methodology NBS used was flawed. When Xi took office in 2012, 58% of people in China were living on less than $8.30 per day, in 2022 this had fallen to 21%. At the 19th Party Congress in 2017, Xi stated the primary contradiction of China's conditions in the new era as "the contradiction between the people's ever-growing need for a better life and unbalanced and inadequate development." In this context, "unbalanced" refers to rural-urban inequalities, regional inequalities, inequalities between the rich and poor, and structural imbalances in the economy. "Inadequate" refers to household income share.
Clinical Allergology Clinical Chemistry Clinical Haematology Clinical Immunology and Blood Banking Clinical Microbiology Clinical Pharmacology Molecular Biology and Genetics Reproduction and Fertility Thrombosis and Haemostasis Toxicology The NPU terminology is supported by a joint committee (C-SC-NPU) of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and a subcommittee of the International Union of Pure and Applied Chemistry (IUPAC). The terminology is freely available for download in its generic version (in English [3]) and various language versions. The specific syntax and the references to international terminologies, classifications and nomenclatures make the terminology definitions language-independent.
To overcome this, GLP-1 receptor agonists and DPP-4 inhibitors have been developed to increase GLP-1 activity. As opposed to common treatment agents such as insulin and sulphonylureas, GLP-1-based treatment has been associated with weight loss and a lower risk of hypoglycemia, two important considerations for patients with type 2 diabetes.
Sources: en.wikipedia.org
=== Tyrannosaurus imperator and Tyrannosaurus regina === In a 2022 study, Gregory S. Paul and colleagues argued that Tyrannosaurus rex, as traditionally understood, actually represents three species: the type species Tyrannosaurus rex, and two previously unrecognized species: T. imperator (meaning "tyrant lizard emperor") and T. regina (meaning "tyrant lizard queen"). The holotype of the former (T. imperator) is the Sue specimen, and the holotype of the latter (T. regina) is Wankel rex. The division into multiple species was primarily based on the high degree of variation in the proportions and robusticity of the femur (and other skeletal elements) across T. rex specimens. Presumed robust and gracile morphotypes and the number of small incisiform teeth in the dentary were also used as a line of evidence. Paul and colleagues categorized the species as follows: T. rex demonstrates robust anatomy, a moderate ratio of femur length vs circumference, and the possession of a singular slender incisiform dentary tooth, T. imperator is robust with a small femur length to circumference ratio and two of the slender teeth, and T. regina is more gracile with a high femur ratio and one of the slender teeth. However, several leading paleontologists, including Stephen Brusatte, Thomas Carr, Thomas Holtz, David Hone, Jingmai O'Connor, and Lindsay Zanno, criticized the study or expressed skepticism of its conclusions.
CTNS is the gene that encodes the protein cystinosin in humans. Cystinosin is a lysosomal seven-transmembrane protein that functions as an active transporter for the export of cystine molecules out of the lysosome. Mutations in CTNS are responsible for cystinosis, an autosomal recessive lysosomal storage disease.
From this colony later originated the founding of Paestum (in Lucania), Lao (at the mouth of the river of the same name) and Scidros (between Cetraro and Belvedere Marittimo). Ionian colonies were Clampetia (in the area between Amantea and San Lucido), Temesa (between Amantea and Nocera Terinese), Terina (in the plain of Sant'Eufemia), Krimisa (Cirò Marina), Petelia (Strongoli). In 743 BCE Achaean settlers instead founded Kroton (current Crotone), on the point now known as Capo Colonna. Crotonians and Sybarites later became rivals. Crotonians founded the colonies of Caulonia (near today's Monasterace Marina) and Scillezio (Squillace). Around 700 BCE Crotonian colonists founded Bristacia, current Umbriatico. Around 680 BCE colonists from the Greek Locris founded Epizephyrian Locris, near present-day Locri. Locrians founded Hipponion (Vibo Valentia) and Medma (Rosarno). The Bruttians, similar to the neighboring Lucanians, declared themselves independent of their “cousins” from beyond the Pollino around the 4th century BCE, forming a confederate state. The capital of the federates was Consentia, present-day Cosenza. It was one of the main cities along with Pandosia, a city whose traces have been lost; some historical references locate it among the municipalities of Castrolibero, Marano Principato, and Marano Marchesato, while other recent archaeological discoveries locate the city near the present city of Acri, Aufugum (Montalto Uffugo), Argentanum (San Marco Argentano), Bergae, Besidiae (Bisignano), and Lymphaeum (Luzzi).
In the 1826 General Convention of Friendship, Commerce and Navigation with the king of Denmark, the United States recognised Greenland as a northern possession of the king, and accepted the trade restrictions that Denmark imposed there. In the Treaty of the Danish West Indies, signed in 1916, the US government explicitly recognised Danish sovereignty over all of Greenland. In the 1941 US–Danish agreement, the American Government "reiterate[d] its recognition of and respect for the sovereignty of the Kingdom of Denmark over Greenland". During World War II, the United States defended Greenland at the request of Danish and Greenlandic officials acting without approval from the central government of Denmark, while it was under Nazi occupation. In the 1951 Greenland Defense Agreement, the United States again recognised the sovereignty of the Kingdom of Denmark over all of Greenland. In the 2004 amendment to the Greenland Defense Agreement, the United States recognised Greenland as "an equal part of the Kingdom of Denmark under the Constitution [with] a wide ranging Greenland Home Rule".
Sources: en.wikipedia.org
Treatment of cancer cells with peptide δ-361 finally resulted to microtubule destabilization and cell death. Fine-mapping of the DDX3X interaction domains on CK1δ, the CK1δ- peptides δ-1, and δ-41 were identified to be able to block the interactions of CK1δ with the X-linked DEAD box RNA helicase DDX3X as well as the kinase activity of CK1δ. In addition, these two identified peptides could inhibit the stimulation of CK1 kinase activity in established cell lines. Since DDX3X mutations being present in medulloblastoma patients increase the activity of CK1 in living cells, and subsequently activate CK1-regulated pathways like Wnt/β-catenin and hedgehog signaling, the identified interaction-blocking peptides could be useful in personalized therapy concepts for the treatment of Wnt/β-catenin- or Hedgehog-driven cancers. In 2018, the interaction between Axin1, a scaffold protein exhibiting important roles in Wnt signaling, and CK1δ/ε were fine-mapped using a peptide library. The identified Axin1 derived peptides were able to block the interaction with CK1δ/ε. Since Axin1 and Dvl also compete for CK1δ/ε-mediated site-specific phosphorylation it can be stated that Axin 1 plays an important role of in balancing CK1δ/ε mediated phosphorylation of Dvl as well as for the activation of canonical Wnt signaling.
=== 2024 Wayanad landslides === In August 2024, the Karnataka government deputed Lad to assist rescue and relief operations in Wayanad, Kerala, following devastating landslides. He camped in the affected area and coordinated with the Kerala government and Karnataka officials concerning people from Karnataka who were stranded or affected.
Eddy stayed there for two years, from 1868 to 1870, teaching Wentworth with Quimby's unpublished essay, "Questions and Answers." She acknowledged that the manuscript was Quimby's, and spoke often of how she had promised to teach his healing method, which at the time she called Moral Science.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.